E Fund Management’s Arcus Biosciences RCUS Stock Holding History

E Fund Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$313K	Buy	+14,473	New	+$313K	0.01%	387
2025 Q2	$89.4K	Buy	10,987 +489	+5%	+$4.18K	﹤0.01%	378
2025 Q1	$82.4K	Buy	+10,498	New	+$122K	﹤0.01%	388
2024 Q2	–	Sell	-16,052	Closed	-$303K	–	365
2024 Q1	$303K	Buy	16,052 +2,551	+19%	+$44.1K	0.02%	274
2023 Q4	$258K	Sell	13,501 -1,537	-10%	-$24.6K	0.02%	252
2023 Q3	$270K	Sell	15,038 -1,098	-7%	-$22.1K	0.02%	220
2023 Q2	$328K	Sell	16,136 -7,199	-31%	-$137K	0.03%	207
2023 Q1	$426K	Buy	23,335 +13,121	+128%	+$251K	0.03%	146
2022 Q4	$211K	Sell	10,214 -5,506	-35%	-$152K	0.02%	295
2022 Q3	$411K	Sell	15,720 -2,055	-12%	-$54.3K	0.04%	176
2022 Q2	$450K	Buy	17,775 +9,670	+119%	+$237K	0.04%	164
2022 Q1	$256K	Buy	+8,105	New	+$272K	0.01%	254

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

E Fund Management's RCUS Position: Q1 2026 in Review

E Fund Management opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 14,473 shares worth $313K. The stake represents 0.01% of the portfolio and ranks #387 among its holdings. This is a return to the name: E Fund Management previously reported a position in RCUS as recently as Q2 2025.

E Fund Management first reported a position in RCUS in Q1 2022 and has held it in 12 quarters since. The position peaked at $450K in Q2 2022. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

E Fund Management held 14,473 shares of Arcus Biosciences worth $313K as of Q1 2026.
Arcus Biosciences was a new E Fund Management position in Q1 2026.
Arcus Biosciences made up 0.01% of E Fund Management's portfolio in Q1 2026, its #387 holding.
E Fund Management first reported a position in Arcus Biosciences in Q1 2022 and has held it in 12 quarters since.
E Fund Management's Arcus Biosciences position peaked at $450K in Q2 2022.
210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.